Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer.

Cancer research - 15 Nov 2016

Ushijima Toshikazu, Yoshino Takayuki

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to KRAS gene
Share to Mutation
Share to Precision Medicine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 28148677
DOI: 10.1158/0008-5472.CAN-16-2867

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 20 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer.PMID 28148677Read ↗

Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer.Semantic proximity Read ↗

Precision oncology for KRASG12C-mutant colorectal cancer.Semantic proximity Read ↗

Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.Semantic proximity Read ↗

Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg.Semantic proximity Read ↗

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistanceSemantic proximity Read ↗

Drugging KRAS: current perspectives and state-of-art review.Semantic proximity Read ↗

KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine.Semantic proximity Read ↗

KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

A bright future for KRAS inhibitors.Semantic proximity Read ↗

Personalized medicine and anti-EGFR antibody therapy in the treatment of metastatic colorectal cancer: KRAS and beyond.Semantic proximity Read ↗

Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies.Semantic proximity Read ↗

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.